Immunome: AL102 And Other Established Protein Targets Could Drive Value [Seeking Alpha]
Immunome, Inc. (IMNM)
Company Research
Source: Seeking Alpha
The global desmoid tumor market is projected to grow to $5.49 billion by 2032. IM-1021 is an antibody-drug conjugate being developed to target ROR1 expressing solid tumors; IND filing to begin a phase 1 study for this program, expected Q1 of 2025. IM-3050 is a radio-ligand therapy being developed to target FAP expressing solid tumors; IND filing to begin a phase 1 study for this program, expected Q1 of 2025. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » Immunome, Inc. NASDAQ: IMNM ) is an interesting biotech to consider, and that's because it has various therapy types it deploys for its pipeline. One of the lead assets it has is AL102, which is being explored in the ongoing phase 3 RINGSIDE study for the treatment of patients with desmoid tumors. Enrollment for Part B of this study was completed back in February 2024 and data from this is expected to be released in the 2
Show less
Read more
Impact Snapshot
Event Time:
IMNM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMNM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMNM alerts
High impacting Immunome, Inc. news events
Weekly update
A roundup of the hottest topics
IMNM
News
- Immunome: Enthusiasm For New Management Has Faded [Seeking Alpha]Seeking Alpha
- Immunome Appoints Phil Tsai as Chief Technical Officer [Yahoo! Finance]Yahoo! Finance
- Immunome Appoints Phil Tsai as Chief Technical OfficerBusiness Wire
- Immunome, Inc. (NASDAQ: IMNM) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $27.00 price target on the stock.MarketBeat
- Immunome Announces Completion of Purchase of Assets from Atreca [Yahoo! Finance]Yahoo! Finance
IMNM
Earnings
- 5/14/24 - Miss
IMNM
Sec Filings
- 6/18/24 - Form 4
- 6/18/24 - Form 3
- 6/18/24 - Form 4
- IMNM's page on the SEC website